Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on developing treatments for cancer patients. Two programs anchor the Company's research platform : Genasense^® (oblimersen sodium) and Tesetaxel a leading Anti-Tublin Agent.

Genasense is the first oncology drug of its kind to directly target the biochemical pathway (known as apoptosis) whereby cancer cells are ultimately killed by chemotherapy. Genasense is believed to inhibit the production of Bcl-2, a protein that is highly expressed in malignant melanoma and is believed to be a fundamental cause of resistance to anticancer therapy. By inhibiting Bcl-2 Genasense may greatly improve the activity of anticancer therapy. Genasense is currently being evaluated in a melanoma study known as Agenda with Overall Survival expected in March 2011.

Tesetaxel is a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. However, both prototype agents suffer from serious safety issues, particularly hypersensitivity reactions related to intravenous infusions that are occasionally fatal and that require careful premedication and observation. Other prominent side-effects of this drug class include myelosuppression (low blood counts) and peripheral neuropathy (disabling nerve damage). Tesetaxel has demonstrated anticancer activity in several Phase 2 clinical trials. The drug has not been associated with severe infusion reactions that are linked with other taxanes. Moreover, unlike other oral taxanes, nerve damage has not been a prominent side effect of tesetaxel. Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity. More than 250 patients worldwide have been treated with oral tesetaxel in Phase 1 and Phase 2 clinical trials

The leading drug in Genta's Small Molecule program is Ganite^®(gallium nitrate injection) , which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss.

For additional information, visit the company website at www.genta.com